During the recent session, Metagenomi Inc (NASDAQ:MGX)’s traded shares were 0.52 million. At the last check today, the stock’s price was $3.87, reflecting an intraday gain of 7.20% or $0.26. The 52-week high for the MGX share is $12.74, that puts it down -229.2 from that peak though still a striking 58.4% gain since the share price plummeted to a 52-week low of $1.61. The company’s market capitalization is $144.83M, and the average intraday trading volume over the past 10 days was 1.52 million shares, and the average trade volume was 1.81 million shares over the past three months.
Metagenomi Inc (MGX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. MGX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.58.
Metagenomi Inc (NASDAQ:MGX) trade information
Metagenomi Inc (MGX) registered a 7.20% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.20% in intraday trading to $3.87, hitting a weekly high. The stock’s 5-day price performance is 2.65%, and it has moved by 86.06% in 30 days. The short interest in Metagenomi Inc (NASDAQ:MGX) is 1.48 million shares and it means that shorts have 0.37 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 44.71% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, MGX is trading at a discount of -80.88% off the target high and -80.88% off the low.
Metagenomi Inc (MGX) estimates and forecasts
Statistics show that Metagenomi Inc has outperformed its competitors in share price, compared to the industry in which it operates. Metagenomi Inc (MGX) shares have gone down -1.02% during the last six months, with a year-to-date growth rate more than the industry average at 87.73% against 16.70. In the rating firms’ projections, revenue will increase 15.35% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.46M as predicted by 5 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 6.25M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 12.4M and 11.16M respectively. In this case, analysts expect current quarter sales to shrink by -23.70% and then drop by -43.99% in the coming quarter.
MGX Dividends
Metagenomi Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
